https://news.medxy.ai/ja/gestational-diabetes-treatment-comparison/Medxy AIja2026-11-02T04:58:39-08:00妊娠糖尿病における経口血糖降下薬とインスリンの比較：SUGAR-DIPランダム化比較試験に基づく社会的費用効果分析 https://news.medxy.ai/vi/oral-medication-vs-insulin/Medxy AIvi2026-11-02T04:58:18-08:00Thuốc hạ đường huyết đường uống hay insulin cho đái tháo đường thai kỳ? Phân tích chi phí-hiệu quả xã hội từ thử nghiệm SUGAR-DIP https://news.medxy.ai/oral-antihyperglycemic-agents-versus-insulin-for-gestational-diabetes-mellitus-societal-cost-effectiveness-analysis-of-the-sugar-dip-randomized-controlled-trial/Medxy AIen2026-11-02T04:58:01-08:00Oral Antihyperglycemic Agents Versus Insulin for Gestational Diabetes Mellitus: Societal Cost-Effectiveness Analysis of the SUGAR-DIP Randomized Controlled Trial https://news.medxy.ai/zh/saroglitazar-primary-biliary-cholangitis/Medxy AIzh2026-11-02T04:57:25-08:00Saroglitazar在原发性胆汁性胆管炎中的应用：来自2b/3期自适应随机试验的启示 https://news.medxy.ai/ja/saroglitazar-primary-biliary-cholangitis-3/Medxy AIja2026-11-02T04:57:04-08:00原発性胆汁性胆管炎におけるSaroglitazar：第2b/3相適応的無作為化試験からの知見 https://news.medxy.ai/vi/saroglitazar-primary-biliary-cholangitis-2/Medxy AIvi2026-11-02T04:56:40-08:00Saroglitazar trong xơ đường mật nguyên phát: Những phát hiện từ thử nghiệm ngẫu nhiên thích ứng pha 2b/3 https://news.medxy.ai/zh/us-tia-management-trends/Medxy AIzh2026-11-02T04:55:30-08:00美国急诊科短暂性脑缺血发作管理新趋势：演变、挑战与启示 https://news.medxy.ai/ja/emergency-tia-care-trends/Medxy AIja2026-11-02T04:55:10-08:00米国における一過性脳虚血発作の救急外来対応の変化：動向、課題、示唆 https://news.medxy.ai/vi/transient-ischemic-attack/Medxy AIvi2026-11-02T04:54:50-08:00Cơn thiếu máu não thoáng qua tại khoa cấp cứu Hoa Kỳ: xu hướng, thách thức và ý nghĩa lâm sàng https://news.medxy.ai/evolving-emergency-department-approaches-to-transient-ischemic-attack-in-the-us-trends-challenges-and-implications/Medxy AIen2026-11-02T04:54:31-08:00Evolving Emergency Department Approaches to Transient Ischemic Attack in the US: Trends, Challenges, and Implications https://news.medxy.ai/zh/metyrapone-cardiovascular-benefits/Medxy AIzh2026-11-02T04:53:48-08:00甲吡酮治疗轻度自主性皮质醇分泌：心血管获益与机制启示 https://news.medxy.ai/ja/mild-autonomous-cortisol-secretion-metyrapone-treatment/Medxy AIja2026-11-02T04:53:28-08:00軽度自律性コルチゾール分泌に対するメチラポン治療：心血管への利益と作用機序の示唆 https://news.medxy.ai/vi/low-dose-metyrapone-cortisol-secretion/Medxy AIvi2026-11-02T04:53:04-08:00Điều trị Metyrapone trong Tiết Cortisol Tự Trị Nhẹ: Lợi ích Tim mạch và Những Hiểu biết Cơ chế https://news.medxy.ai/metyrapone-treatment-in-mild-autonomous-cortisol-secretion-cardiovascular-benefits-and-mechanistic-insights/Medxy AIen2026-11-02T04:52:45-08:00Metyrapone Treatment in Mild Autonomous Cortisol Secretion: Cardiovascular Benefits and Mechanistic Insights https://news.medxy.ai/zh/acadm-fatty-acid-oxidation/Medxy AIzh2026-11-02T04:52:04-08:00ACADM介导的脂肪酸β-氧化：动脉粥样硬化与腹主动脉瘤中的差异性脂质代谢通路 https://news.medxy.ai/ja/acadm-fatty-acid-oxidation-vascular-disease-2/Medxy AIja2026-11-02T04:51:42-08:00ACADM介在性脂肪酸β酸化が動脈硬化と腹部大動脈瘤を分ける——血管疾患の異なる脂質代謝経路 https://news.medxy.ai/vi/acadm-lipid-metabolism-vascular-disease/Medxy AIvi2026-11-02T04:51:20-08:00ACADM và β-oxy hóa acid béo trong xơ vữa động mạch và phình động mạch chủ bụng: những con đường chuyển hóa lipid khác biệt trong bệnh lý mạch máu https://news.medxy.ai/acadm-fatty-acid-oxidation-vascular-disease/Medxy AIen2026-11-02T04:50:59-08:00ACADM-Mediated Fatty Acid β-Oxidation in Atherosclerosis and Abdominal Aortic Aneurysm: Distinct Lipid Metabolic Pathways Underlying Vascular Disease https://news.medxy.ai/zh/persistent-postoperative-inflammation/Medxy AIzh2026-11-02T04:50:11-08:00前交叉韧带重建后炎症与软骨生物标志物持续异常：术后关节生物学的新认识 https://news.medxy.ai/ja/inflammation-cartilage-biomarkers/Medxy AIja2026-11-02T04:49:53-08:00ACL再建後も続く炎症・軟骨バイオマーカーの変化――術後関節生物学の新知見 https://news.medxy.ai/vi/persistent-inflammatory-markers/Medxy AIvi2026-11-02T04:49:31-08:00Biến đổi kéo dài của các dấu ấn viêm và sụn sau tái tạo dây chằng chéo trước: Những gợi ý về sinh học khớp sau phẫu thuật https://news.medxy.ai/persistent-alterations-in-inflammatory-and-cartilage-biomarkers-following-anterior-cruciate-ligament-reconstruction-insights-into-postoperative-joint-biology/Medxy AIen2026-11-02T04:49:12-08:00Persistent Alterations in Inflammatory and Cartilage Biomarkers Following Anterior Cruciate Ligament Reconstruction: Insights Into Postoperative Joint Biology https://news.medxy.ai/zh/traumatic-brain-injury-reoffending-reduction/Medxy AIzh2026-11-02T04:48:27-08:00创伤性脑损伤患者再犯率降低：RCBI试验揭示出狱前后连续干预的价值 https://news.medxy.ai/ja/reducing-reoffending-after-brain-injury/Medxy AIja2026-11-02T04:48:06-08:00外傷性脳損傷患者の再犯を減らすには：RCBI試験が示した再統合支援の成果 https://news.medxy.ai/vi/reducing-recidivism-brain-injury/Medxy AIvi2026-11-02T04:47:48-08:00Giảm tái phạm ở bệnh nhân chấn thương sọ não: Những phát hiện từ thử nghiệm Re-entry Continuum for Brain Injury (RCBI) https://news.medxy.ai/reducing-recidivism-in-traumatic-brain-injury-patients-insights-from-the-re-entry-continuum-for-brain-injury-rcbi-trial/Medxy AIen2026-11-02T04:47:30-08:00Reducing Recidivism in Traumatic Brain Injury Patients: Insights from the Re-entry Continuum for Brain Injury (RCBI) Trial https://news.medxy.ai/zh/osimertinib-savolitinib-survival-benefit/Medxy AIzh2026-11-02T04:46:27-08:00奥希替尼联合萨沃替尼为晚期 EGFR 突变 NSCLC 合并 MET 异常患者带来生存获益 https://news.medxy.ai/ja/osimertinib-savolitinib-saffron-trial/Medxy AIja2026-11-02T04:46:08-08:00オシメルチニブ後進行のMET異常を伴う進行EGFR変異NSCLCに対するオシメルチニブ＋サボリチニブ併用療法：生存期間改善を示した第3相SAFFRON試験 https://news.medxy.ai/vi/osimertinib-savolitinib-survival/Medxy AIvi2026-11-02T04:45:45-08:00Kéo dài sống còn với phối hợp Osimertinib và Savolitinib ở NSCLC tiến triển có đột biến EGFR và rối loạn MET sau khi kháng osimertinib https://news.medxy.ai/enhanced-survival-with-osimertinib-and-savolitinib-combination-in-advanced-egfr-mutated-nsclc-with-met-dysregulation-post-osimertinib-progression/Medxy AIen2026-11-02T04:45:27-08:00Enhanced Survival with Osimertinib and Savolitinib Combination in Advanced EGFR-Mutated NSCLC with MET Dysregulation Post-Osimertinib Progression https://news.medxy.ai/saroglitazar-in-primary-biliary-cholangitis-insights-from-a-phase-2b-3-adaptive-randomized-trial/Medxy AIen2026-11-02T00:56:19-08:00Saroglitazar in Primary Biliary Cholangitis: Insights from a Phase 2b/3 Adaptive Randomized Trial https://news.medxy.ai/ehealth-guided-exercise-enhances-peak-oxygen-uptake-and-quality-of-life-post-covid-19-a-randomized-controlled-trial/Medxy AIen2026-11-02T00:24:43-08:00eHealth-Guided Exercise Enhances Peak Oxygen Uptake and Quality of Life Post-COVID-19: A Randomized Controlled Trial https://news.medxy.ai/zh/bankart-repair-outcomes-2/Medxy AIzh2026-11-01T02:55:06-08:00年轻运动员关节镜下Bankart修复5年结局：复发、重返运动与风险因素 https://news.medxy.ai/ja/five-year-bankart-outcomes/Medxy AIja2026-11-01T02:54:49-08:00若年アスリートにおける軽度glenoid bone lossを伴うarthroscopic Bankart修復術の5年成績：再発、スポーツ復帰、危険因子 https://news.medxy.ai/vi/five-year-bankart-outcomes-2/Medxy AIvi2026-11-01T02:54:24-08:00Kết quả 5 năm sau phẫu thuật Bankart nội soi ở vận động viên trẻ có mất xương ổ chảo tối thiểu: tái phát, quay lại thể thao và yếu tố nguy cơ https://news.medxy.ai/five-year-outcomes-of-arthroscopic-bankart-repair-in-young-athletes-with-minimal-glenoid-bone-loss-recurrence-return-to-sport-and-risk-factors/Medxy AIen2026-11-01T02:54:07-08:00Five-Year Outcomes of Arthroscopic Bankart Repair in Young Athletes With Minimal Glenoid Bone Loss: Recurrence, Return to Sport, and Risk Factors https://news.medxy.ai/zh/age-differences-stroke-outcomes/Medxy AIzh2026-11-01T02:53:28-08:00年龄差异如何影响长期多模式卒中干预结局：LAST-long 试验带来的启示 https://news.medxy.ai/ja/age-impact-stroke-outcomes/Medxy AIja2026-11-01T02:53:08-08:00年齢差が長期多面的脳卒中介入の転帰を左右する：LAST-long試験からの知見 https://news.medxy.ai/vi/age-and-long-term-stroke-rehabilitation/Medxy AIvi2026-11-01T02:52:45-08:00Tuổi ảnh hưởng rõ rệt đến hiệu quả của can thiệp đa mô thức dài hạn sau đột quỵ: phân tích từ thử nghiệm LAST-long https://news.medxy.ai/age-related-differences-influence-outcomes-of-long-term-multimodal-stroke-intervention-insights-from-the-last-long-trial/Medxy AIen2026-11-01T02:52:26-08:00Age-Related Differences Influence Outcomes of Long-Term Multimodal Stroke Intervention: Insights from the LAST-long Trial https://news.medxy.ai/zh/oral-health-liver-cancer-risk/Medxy AIzh2026-11-01T02:51:39-08:00口腔健康与肝癌风险的关联：来自瑞典全国队列研究的启示 https://news.medxy.ai/ja/oral-health-liver-cancer-risk-2/Medxy AIja2026-11-01T02:51:20-08:00口腔衛生は肝癌リスクにどう関わるのか？スウェーデン全国コホート研究が示した新知見 https://news.medxy.ai/vi/oral-health-liver-cancer/Medxy AIvi2026-11-01T02:50:57-08:00Sức khỏe răng miệng có liên quan đến nguy cơ ung thư gan: Những phát hiện từ một nghiên cứu đoàn hệ toàn quốc tại Thụy Điển https://news.medxy.ai/linking-oral-health-to-liver-cancer-risk-insights-from-a-nationwide-swedish-cohort-study/Medxy AIen2026-11-01T02:50:37-08:00Linking Oral Health to Liver Cancer Risk: Insights from a Nationwide Swedish Cohort Study https://news.medxy.ai/zh/mitapivat-sickle-cell-disease/Medxy AIzh2026-11-01T02:49:53-08:00Mitapivat治疗镰状细胞病：一种有望改善溶血性贫血并减少并发症的口服新疗法 https://news.medxy.ai/ja/mitapivat-sickle-cell-disease-2/Medxy AIja2026-11-01T02:49:29-08:00鎌状赤血球症におけるミタピバット：溶血性貧血の改善と合併症減少が期待される新規経口治療 https://news.medxy.ai/vi/mitapivat-sickle-cell-anemia/Medxy AIvi2026-11-01T02:49:03-08:00Mitapivat trong bệnh hồng cầu hình liềm: Liệu pháp đường uống đầy hứa hẹn giúp cải thiện thiếu máu tan máu và giảm biến chứng https://news.medxy.ai/mitapivat-in-sickle-cell-disease-a-promising-oral-therapy-to-improve-hemolytic-anemia-and-reduce-complications/Medxy AIen2026-11-01T02:48:43-08:00Mitapivat in Sickle Cell Disease: A Promising Oral Therapy to Improve Hemolytic Anemia and Reduce Complications https://news.medxy.ai/zh/hydrocephalus-treatment-advances/Medxy AIzh2026-11-01T02:47:56-08:00脑积水治疗新进展：前沿研究与持续挑战 https://news.medxy.ai/ja/hydrocephalus-treatment-research/Medxy AIja2026-11-01T02:47:37-08:00水頭症治療の最前線：新規研究と残された課題 https://news.medxy.ai/vi/hydrocephalus-treatment-advance/Medxy AIvi2026-11-01T02:47:16-08:00Tiền tuyến trong điều trị não úng thủy: Các nghiên cứu mới và những thách thức còn tồn tại https://news.medxy.ai/hydrocephalus-advances-in-treatment-emerging-research-and-ongoing-challenges/Medxy AIen2026-11-01T02:47:04-08:00Hydrocephalus: Advances in Treatment, Emerging Research, and Ongoing Challenges https://news.medxy.ai/zh/antibody-remodeling-antiphospholipid-syndrome/Medxy AIzh2026-11-01T02:46:22-08:00BAFF-APRIL 阻断下抗磷脂综合征中同型特异性自身抗体的重塑 https://news.medxy.ai/ja/isotype-specific-autoantibody-reconstruction/Medxy AIja2026-11-01T02:45:57-08:00BAFF-APRIL遮断による抗リン脂質症候群のアイソタイプ特異的自己抗体再構築 https://news.medxy.ai/vi/isotype-specific-autoantibody-restructuring/Medxy AIvi2026-11-01T02:45:33-08:00Tái cấu trúc autoantibody đặc hiệu theo isotype trong hội chứng kháng phospholipid qua ức chế BAFF-APRIL https://news.medxy.ai/isotype-specific-autoantibody-remodeling-in-antiphospholipid-syndrome-via-baff-april-blockade/Medxy AIen2026-11-01T02:45:12-08:00Isotype-Specific Autoantibody Remodeling in Antiphospholipid Syndrome via BAFF-APRIL Blockade https://news.medxy.ai/zh/energy-recovery-after-heart-transplant/Medxy AIzh2026-11-01T02:44:26-08:00心脏移植后的能量恢复与心肌效率：一项探索性研究的启示 https://news.medxy.ai/ja/energy-recovery-heart-transplantation/Medxy AIja2026-11-01T02:44:04-08:00心臓移植後のエネルギー回復と心筋効率：探索的研究からの知見 https://news.medxy.ai/vi/energy-recovery-for-heart-transplantation/Medxy AIvi2026-11-01T02:43:41-08:00Sự phục hồi năng lượng và hiệu quả cơ tim sau ghép tim: Những hiểu biết từ một nghiên cứu thăm dò https://news.medxy.ai/energetic-recovery-and-myocardial-efficiency-after-heart-transplantation-insights-from-an-exploratory-study/Medxy AIen2026-11-01T02:43:23-08:00Energetic Recovery and Myocardial Efficiency After Heart Transplantation: Insights from an Exploratory Study https://news.medxy.ai/zh/hmme-pdt-vs-pulsed-dye-laser/Medxy AIzh2026-11-01T02:42:35-08:00HMME-PDT 与脉冲染料激光治疗面颈部葡萄酒色斑的疗效与安全性比较：一项大型回顾性研究启示 https://news.medxy.ai/ja/port-wine-stain-treatment/Medxy AIja2026-11-01T02:42:14-08:00顔面・頸部ポートワイン母斑に対するHMME-PDTとパルス色素レーザーの比較：大規模後ろ向き研究からの知見 https://news.medxy.ai/vi/hmme-pdt-vs-pulsed-dye-laser-2/Medxy AIvi2026-11-01T02:41:56-08:00HMME-PDT hay laser nhuộm xung: phương pháp nào hiệu quả và an toàn hơn trong điều trị u máu rượu vang vùng mặt – cổ? https://news.medxy.ai/comparative-effectiveness-and-safety-of-hmme-pdt-versus-pulsed-dye-laser-in-treating-facial-and-neck-port-wine-stains-insights-from-a-large-retrospective-study/Medxy AIen2026-11-01T02:41:37-08:00Comparative Effectiveness and Safety of HMME-PDT Versus Pulsed Dye Laser in Treating Facial and Neck Port-Wine Stains: Insights from a Large Retrospective Study https://news.medxy.ai/zh/arterial-pressure-gradient-in-vasoactive-therapy/Medxy AIzh2026-11-01T02:40:54-08:00危重患者血管活性治疗中肱动脉-桡动脉动脉压梯度的临床意义 https://news.medxy.ai/ja/clinical-significance-of-pressure-gradient/Medxy AIja2026-11-01T02:40:33-08:00昇圧薬治療中の重症患者における上腕動脈－橈骨動脈圧較差の臨床的意義 https://news.medxy.ai/vi/arterial-pressure-gradient/Medxy AIvi2026-11-01T02:40:08-08:00Chênh lệch áp lực động mạch giữa cánh tay và quay ở bệnh nhân nặng dùng thuốc vận mạch: Ý nghĩa lâm sàng https://news.medxy.ai/clinical-implications-of-brachial-to-radial-arterial-pressure-gradients-in-critically-ill-patients-on-vasoactive-therapy/Medxy AIen2026-11-01T02:39:50-08:00Clinical Implications of Brachial-to-Radial Arterial Pressure Gradients in Critically Ill Patients on Vasoactive Therapy https://news.medxy.ai/zh/alcohol-prescribing-gaps/Medxy AIzh2026-11-01T02:39:05-08:00住院出院时酒精使用障碍处方为何偏低？关键预测因素与干预切入点 https://news.medxy.ai/ja/factors-in-aud-medication-prescribing/Medxy AIja2026-11-01T02:38:46-08:00退院時のAUD治療薬処方を左右する要因とは：治療ギャップを埋める鍵を探る https://news.medxy.ai/vi/alcohol-discharge-prescriptions/Medxy AIvi2026-11-01T02:38:24-08:00Đơn thuốc khi xuất viện cho rối loạn sử dụng rượu: Những yếu tố dự báo then chốt để thu hẹp khoảng trống điều trị https://news.medxy.ai/hospital-discharge-prescriptions-for-alcohol-use-disorder-unveiling-key-predictors-to-bridge-the-treatment-gap/Medxy AIen2026-11-01T02:38:04-08:00Hospital Discharge Prescriptions for Alcohol Use Disorder: Unveiling Key Predictors to Bridge the Treatment Gap https://news.medxy.ai/zh/thrombin-responsive-fviii-antibody/Medxy AIzh2026-11-01T02:37:22-08:00凝血酶响应型自我调节FVIII模拟抗体：让血友病A治疗更安全 https://news.medxy.ai/ja/safer-hemophilia-a-treatment/Medxy AIja2026-11-01T02:37:01-08:00より安全な血友病A治療へ：トロンビン応答型の自己調節FVIII模倣抗体 https://news.medxy.ai/vi/safer-hemophilia-treatment/Medxy AIvi2026-11-01T02:36:40-08:00Kháng thể mô phỏng FVIII tự điều hòa đáp ứng thrombin: hướng đi mới giúp điều trị hemophilia A an toàn hơn https://news.medxy.ai/innovative-thrombin-responsive-autoregulated-fviii-mimetic-antibodies-for-safer-hemophilia-a-therapy/Medxy AIen2026-11-01T02:36:22-08:00Innovative Thrombin-Responsive AutoRegulated FVIII-Mimetic Antibodies for Safer Hemophilia A Therapy https://news.medxy.ai/zh/lung-cancer-screening-follow-up/Medxy AIzh2026-11-01T02:35:40-08:00破解社区肺癌筛查随访难题：ACCELL试验带来的启示 https://news.medxy.ai/ja/overcoming-follow-up-barriers/Medxy AIja2026-11-01T02:35:20-08:00地域医療における肺がんスクリーニング後フォローアップの障壁をどう乗り越えるか：ACCELL試験からの示唆 https://news.medxy.ai/vi/overcoming-lung-screening-barriers/Medxy AIvi2026-11-01T02:34:59-08:00Vượt Qua Rào Cản Theo Dõi Sàng Lọc Ung Thư Phổi Trong Chăm Sóc Cộng Đồng: Góc Nhìn Từ Thử Nghiệm ACCELL https://news.medxy.ai/navigating-barriers-to-lung-cancer-screening-follow-up-in-community-care-insights-from-the-accell-trial/Medxy AIen2026-11-01T02:34:42-08:00Navigating Barriers to Lung Cancer Screening Follow-Up in Community Care: Insights from the ACCELL Trial https://news.medxy.ai/zh/glaucoma-visual-field-progression/Medxy AIzh2026-11-01T02:33:58-08:00青光眼视野再次进展：发生率、危险因素与临床意义 https://news.medxy.ai/ja/glaucoma-field-progression-recurrence/Medxy AIja2026-11-01T02:33:40-08:00緑内障の視野進行は再発するのか？発生率・危険因子・臨床的意義を検証 https://news.medxy.ai/vi/glaucoma-visual-field-progression-2/Medxy AIvi2026-11-01T02:33:20-08:00Glaucoma: nguy cơ tái phát tiến triển thị trường, các yếu tố dự báo và ý nghĩa lâm sàng https://news.medxy.ai/recurrent-visual-field-progression-in-glaucoma-incidence-risk-factors-and-clinical-implications/Medxy AIen2026-11-01T02:33:03-08:00Recurrent Visual Field Progression in Glaucoma: Incidence, Risk Factors, and Clinical Implications https://news.medxy.ai/zh/music-perception-hearing-devices/Medxy AIzh2026-11-01T02:32:23-08:00低频退化下音乐音质如何被感知？助听器与人工耳蜗的差异比较 https://news.medxy.ai/ja/low-frequency-sound-perception/Medxy AIja2026-11-01T02:32:07-08:00補聴器と人工内耳でみる低周波数音質知覚：音楽の聴こえ方の違いを検証 https://news.medxy.ai/vi/low-frequency-music-quality/Medxy AIvi2026-11-01T02:31:45-08:00Cảm nhận chất lượng âm nhạc ở dải tần thấp trong các thiết bị hỗ trợ thính giác: So sánh máy trợ thính và ốc tai điện tử https://news.medxy.ai/perception-of-low-frequency-musical-sound-quality-in-hearing-assistive-devices-comparing-hearing-aids-and-cochlear-implants/Medxy AIen2026-11-01T02:31:29-08:00Perception of Low-Frequency Musical Sound Quality in Hearing-Assistive Devices: Comparing Hearing Aids and Cochlear Implants https://news.medxy.ai/zh/pancreatic-fistula-management/Medxy AIzh2026-11-01T02:30:51-08:00远端胰腺切除术后胰瘘与腹腔积液：发生率、临床影响及处理策略 https://news.medxy.ai/ja/pancreatic-fistula-management-2/Medxy AIja2026-11-01T02:30:31-08:00遠位膵切除術後の膵瘻と腹腔内液体貯留：発生率、臨床的影響、管理戦略 https://news.medxy.ai/vi/pancreatic-leak-management/Medxy AIvi2026-11-01T02:30:07-08:00Rò tụy và ổ dịch trong ổ bụng sau cắt tụy xa: Tỷ lệ mắc, ý nghĩa lâm sàng và chiến lược xử trí https://news.medxy.ai/pancreatic-fistula-and-intra-abdominal-fluid-collections-after-distal-pancreatectomy-incidence-clinical-impact-and-management-strategies/Medxy AIen2026-11-01T02:29:49-08:00Pancreatic Fistula and Intra-abdominal Fluid Collections After Distal Pancreatectomy: Incidence, Clinical Impact, and Management Strategies https://news.medxy.ai/zh/early-abortion-follow-up-optimization/Medxy AIzh2026-11-01T02:29:04-08:00新西兰早期药物流产随访方式优化：随机对照试验证实自我评估优于血清bhCG检测 https://news.medxy.ai/ja/early-abortion-follow-up-improvements/Medxy AIja2026-11-01T02:28:46-08:00ニュージーランドで明らかになった早期医療的中絶後フォローアップの改善策：自己評価と血清bhCG検査を比較したランダム化比較試験 https://news.medxy.ai/vi/early-abortion-follow-up/Medxy AIvi2026-11-01T02:28:23-08:00Tăng cường theo dõi sau phá thai nội khoa sớm tại New Zealand: Bằng chứng từ thử nghiệm ngẫu nhiên có đối chứng về tự đánh giá so với xét nghiệm beta-hCG huyết thanh https://news.medxy.ai/enhancing-follow-up-after-early-medical-abortion-in-new-zealand-evidence-from-a-randomised-controlled-trial-on-self-assessment-versus-serum-bhcg-testing/Medxy AIen2026-11-01T02:28:03-08:00Enhancing Follow-Up After Early Medical Abortion in New Zealand: Evidence from a Randomised Controlled Trial on Self-Assessment versus Serum bhCG Testing https://news.medxy.ai/zh/miricorilant-mash-trial/Medxy AIzh2026-11-01T02:27:17-08:00MASH治疗新进展：miricorilant 1b期研究结果积极，间歇给药方案更具潜力 https://news.medxy.ai/ja/miricorilant-for-mash-intermittent-dosing/Medxy AIja2026-11-01T02:26:56-08:00MASH治療の新たな進展：miricorilantの第1b相試験で良好な結果、間欠投与レジメンにさらなる可能性 https://news.medxy.ai/vi/miricorilant-mash-intermittent-dosing/Medxy AIvi2026-11-01T02:26:35-08:00Miricorilant trong viêm gan nhiễm mỡ liên quan rối loạn chức năng chuyển hóa: Kết quả giai đoạn 1b đầy hứa hẹn nhấn mạnh chiến lược dùng liều gián đoạn https://news.medxy.ai/miricorilant-in-metabolic-dysfunction-associated-steatohepatitis-promising-phase-1b-results-highlight-intermittent-dosing-strategy/Medxy AIen2026-11-01T02:26:18-08:00Miricorilant in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 1b Results Highlight Intermittent Dosing Strategy https://news.medxy.ai/zh/dopamine-antagonists-in-huntingtons-disease/Medxy AIzh2026-11-01T02:25:38-08:00亨廷顿病中的多巴胺拮抗剂：来自安慰剂对照试验 PROOF-HD 的证据 https://news.medxy.ai/ja/dopamine-antagonists-in-huntingtons/Medxy AIja2026-11-01T02:25:17-08:00ハンチントン病における抗ドパミン薬：プラセボ対照試験「PROOF-HD」からのエビデンス https://news.medxy.ai/vi/dopamine-antagonists-huntingtons/Medxy AIvi2026-11-01T02:24:51-08:00Thuốc kháng dopamin trong bệnh Huntington: Bằng chứng từ thử nghiệm đối chứng giả dược PROOF-HD https://news.medxy.ai/antidopaminergic-medications-and-clinical-outcomes-in-huntington-disease-insights-from-the-proof-hd-placebo-controlled-trial/Medxy AIen2026-11-01T02:24:30-08:00Antidopaminergic Medications and Clinical Outcomes in Huntington Disease: Insights From the PROOF-HD Placebo-Controlled Trial https://news.medxy.ai/zh/lonapegsomatropin-turner-syndrome-52-week-results/Medxy AIzh2026-11-01T02:23:34-08:00每周一次 Lonapegsomatropin 在 Turner 综合征中的疗效与每日 Somatropin 相当：New InsiGHTS 试验52周结果 https://news.medxy.ai/ja/lonapegsomatropin-for-turner-syndrome/Medxy AIja2026-11-01T02:23:17-08:00Turner syndrome に対する週1回 lonapegsomatropin 療法、日次 somatropin と同等の有効性を示す：New InsiGHTS 試験52週成績 https://news.medxy.ai/vi/weekly-lonapegsomatropin-turner-syndrome/Medxy AIvi2026-11-01T02:22:54-08:00Lonapegsomatropin dùng một lần mỗi tuần cho hiệu quả tương đương somatropin hằng ngày ở hội chứng Turner: Kết quả 52 tuần từ thử nghiệm New InsiGHTS https://news.medxy.ai/lonapegsomatropin-once-weekly-therapy-shows-comparable-efficacy-to-daily-somatropin-in-turner-syndrome-52-week-outcomes-from-the-new-insights-trial/Medxy AIen2026-11-01T02:22:36-08:00Lonapegsomatropin Once-Weekly Therapy Shows Comparable Efficacy to Daily Somatropin in Turner Syndrome: 52-Week Outcomes from the New InsiGHTS Trial https://news.medxy.ai/zh/early-cholesterol-treatment/Medxy AIzh2026-11-01T02:21:58-08:00家族性高胆固醇血症的早期降胆固醇治疗：来自SAFEHEART研究的启示 https://news.medxy.ai/ja/early-cholesterol-lowering-therapy/Medxy AIja2026-11-01T02:21:41-08:00家族性高コレステロール血症に対する早期脂質低下療法：SAFEHEART研究が示す知見 https://news.medxy.ai/vi/early-cholesterol-treatment-safeheart/Medxy AIvi2026-11-01T02:21:18-08:00Điều trị hạ cholesterol sớm trong tăng cholesterol máu gia đình: Những phát hiện từ nghiên cứu SAFEHEART https://news.medxy.ai/early-cholesterol-lowering-therapy-in-familial-hypercholesterolaemia-insights-from-the-safeheart-study/Medxy AIen2026-11-01T02:20:58-08:00Early Cholesterol-Lowering Therapy in Familial Hypercholesterolaemia: Insights from the SAFEHEART Study https://news.medxy.ai/zh/digital-knee-pain-therapy-2/Medxy AIzh2026-11-01T02:20:13-08:00数字疗法可显著减轻慢性髌股关节疼痛 https://news.medxy.ai/ja/digital-knee-pain-therapy/Medxy AIja2026-11-01T02:19:53-08:00運動療法と認知行動療法を統合したデジタル治療が慢性膝蓋大腿痛を有意に軽減　多施設RCT https://news.medxy.ai/vi/digital-therapy-knee-pain/Medxy AIvi2026-11-01T02:19:28-08:00Liệu pháp số tích hợp tập luyện và nhận thức–hành vi giúp giảm rõ rệt đau xương bánh chè–đùi mạn tính: Thử nghiệm ngẫu nhiên đa trung tâm https://news.medxy.ai/integrated-digital-therapeutic-combining-exercise-and-cognitive-behavioural-therapy-significantly-reduces-chronic-patellofemoral-pain-a-multicentre-rct/Medxy AIen2026-11-01T02:19:10-08:00Integrated Digital Therapeutic Combining Exercise and Cognitive-Behavioural Therapy Significantly Reduces Chronic Patellofemoral Pain: A Multicentre RCT https://news.medxy.ai/zh/innovative-bedside-vision-rehab/Medxy AIzh2026-11-01T02:18:28-08:00脑损伤康复中的创新床旁计算机视觉：提升姿势评估的新方案 https://news.medxy.ai/ja/posture-assessment-rehabilitation/Medxy AIja2026-11-01T02:18:09-08:00脳損傷リハビリテーションにおける姿勢評価を高める、革新的なポイント・オブ・ケア・コンピュータービジョン https://news.medxy.ai/vi/point-of-care-posture-assessment/Medxy AIvi2026-11-01T02:17:49-08:00Đánh giá tư thế tại điểm chăm sóc bằng thị giác máy tính: Bước tiến mới trong phục hồi chức năng sau tổn thương não https://news.medxy.ai/innovative-point-of-care-computer-vision-for-enhanced-postural-assessment-in-brain-injury-rehabilitation/Medxy AIen2026-11-01T02:17:32-08:00Innovative Point-of-Care Computer Vision for Enhanced Postural Assessment in Brain Injury Rehabilitation https://news.medxy.ai/zh/canestat-enamel-protection/Medxy AIzh2026-11-01T02:16:56-08:00CaneStat 如何增强釉小皮特性并保护釉质免受侵蚀：一项体内与生物物理学分析 https://news.medxy.ai/ja/canestat-enamel-protection-2/Medxy AIja2026-11-01T02:16:29-08:00CaneStatがエナメルペリクルを強化し、エナメル質侵食から守る役割：in vivo・生物物理学的解析 https://news.medxy.ai/vi/canestat-protects-enamel-teeth/Medxy AIvi2026-11-01T02:16:00-08:00CaneStat cải thiện đặc tính pellicle và bảo vệ men răng khỏi mòn: Phân tích in vivo và lý sinh https://news.medxy.ai/canestats-role-in-enhancing-pellicle-properties-and-protecting-enamel-from-erosion-an-in-vivo-and-biophysical-analysis/Medxy AIen2026-11-01T02:15:40-08:00CaneStat’s Role in Enhancing Pellicle Properties and Protecting Enamel From Erosion: An In Vivo and Biophysical Analysis https://news.medxy.ai/zh/pd-l1-negative-nsclc-breakthrough/Medxy AIzh2026-11-01T02:14:54-08:00PD-L1阴性晚期非鳞状NSCLC一线治疗迎来新突破：sacituzumab tirumotecan联合pembrolizumab https://news.medxy.ai/ja/first-line-therapy-potential/Medxy AIja2026-11-01T02:14:33-08:00PD-L1陰性進行非扁平上皮NSCLCに新局面：sacituzumab tirumotecan＋pembrolizumabが示す一次治療の可能性 https://news.medxy.ai/vi/sacituzumab-pembrolizumab-nsclc/Medxy AIvi2026-11-01T02:14:07-08:00Sacituzumab Tirumotecan kết hợp Pembrolizumab ở NSCLC tiến triển không phải tế bào vảy âm tính với PD-L1: Bước ngoặt trong điều trị hàng đầu https://news.medxy.ai/sacituzumab-tirumotecan-plus-pembrolizumab-in-pd-l1-negative-advanced-non-squamous-nsclc-a-paradigm-shift-in-first-line-therapy/Medxy AIen2026-11-01T02:13:46-08:00Sacituzumab Tirumotecan Plus Pembrolizumab in PD-L1-Negative Advanced Non-Squamous NSCLC: A Paradigm Shift in First-Line Therapy https://news.medxy.ai/zh/hope4abi-sexual-health/Medxy AIzh2026-10-31T06:04:24-07:00HOPE4ABI 数字化干预的可行性与影响：改善卒中及脑损伤后心理与性健康 https://news.medxy.ai/ja/hope4abi-digital-intervention/Medxy AIja2026-10-31T06:04:00-07:00HOPE4ABIの実現可能性と臨床的意義：脳卒中・脳損傷後の心と性のウェルビーイングを支えるデジタル介入 https://news.medxy.ai/vi/hope4abi-intervention-feasibility/Medxy AIvi2026-10-31T06:03:33-07:00HOPE4ABI: Can thiệp số hỗ trợ sức khỏe tinh thần và tình dục sau đột quỵ, tổn thương não có khả thi và hứa hẹn đến đâu? https://news.medxy.ai/feasibility-and-impact-of-hope4abi-a-digital-intervention-enhancing-mental-and-sexual-wellbeing-post-stroke-and-brain-injury/Medxy AIen2026-10-31T06:03:09-07:00Feasibility and Impact of HOPE4ABI: A Digital Intervention Enhancing Mental and Sexual Wellbeing Post-Stroke and Brain Injury https://news.medxy.ai/zh/cost-effectiveness-of-nonsurgical-periodontal-therapy/Medxy AIzh2026-10-31T06:02:30-07:00一般牙科实践中非手术牙周治疗的成本效益比较 https://news.medxy.ai/ja/cost-effectiveness-in-nonsurgical-periodontal-therapy/Medxy AIja2026-10-31T06:02:07-07:00一般歯科診療における非外科的歯周治療の費用対効果の比較 https://news.medxy.ai/vi/cost-effectiveness-of-nonsurgical-periodontal-therapy-2/Medxy AIvi2026-10-31T06:01:43-07:00So sánh hiệu quả chi phí của các liệu pháp nha chu không phẫu thuật trong thực hành tổng quát https://news.medxy.ai/comparative-cost-effectiveness-of-non-surgical-periodontal-therapies-in-general-practice/Medxy AIen2026-10-31T06:01:20-07:00Comparative Cost-Effectiveness of Non-Surgical Periodontal Therapies in General Practice https://news.medxy.ai/zh/refractory-colorectal-cancer-treatment/Medxy AIzh2026-10-31T06:00:41-07:00难治性转移性结直肠癌简化14天曲氟尿苷-替吡嘧啶联合贝伐珠单抗方案的非劣效性：PRABITAS试验解读 https://news.medxy.ai/ja/prabitas-trial-colorectal-cancer/Medxy AIja2026-10-31T06:00:12-07:00難治性転移性大腸がんに対するトリフルリジン・チピラシル＋ベバシズマブ14日間簡略レジメンの非劣性：PRABITAS試験からの知見 https://news.medxy.ai/vi/14-day-trifluridine-tipiracil-bevacizumab-regimen/Medxy AIvi2026-10-31T05:59:39-07:00Phác đồ 14 ngày trifluridine-tipiracil + bevacizumab: hiệu quả không kém hơn và ít độc tính hơn trong ung thư đại trực tràng di căn kháng trị https://news.medxy.ai/non-inferiority-of-a-simplified-14-day-trifluridine-tipiracil-plus-bevacizumab-regimen-for-refractory-metastatic-colorectal-cancer-insights-from-the-prabitas-trial/Medxy AIen2026-10-31T05:59:14-07:00Non-Inferiority of a Simplified 14-Day Trifluridine-Tipiracil plus Bevacizumab Regimen for Refractory Metastatic Colorectal Cancer: Insights from the PRABITAS Trial